106 related articles for article (PubMed ID: 22506516)
1. Discovery of novel allosteric mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors possessing bidentate Ser212 interactions.
Heald RA; Jackson P; Savy P; Jones M; Gancia E; Burton B; Newman R; Boggs J; Chan E; Chan J; Choo E; Merchant M; Rudewicz P; Ultsch M; Wiesmann C; Yue Q; Belvin M; Price S
J Med Chem; 2012 May; 55(10):4594-604. PubMed ID: 22506516
[TBL] [Abstract][Full Text] [Related]
2. Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones.
Wallace EM; Lyssikatos J; Blake JF; Seo J; Yang HW; Yeh TC; Perrier M; Jarski H; Marsh V; Poch G; Livingston MG; Otten J; Hingorani G; Woessner R; Lee P; Winkler J; Koch K
J Med Chem; 2006 Jan; 49(2):441-4. PubMed ID: 16420026
[TBL] [Abstract][Full Text] [Related]
3. 4-anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase.
Spicer JA; Rewcastle GW; Kaufman MD; Black SL; Plummer MS; Denny WA; Quin J; Shahripour AB; Barrett SD; Whitehead CE; Milbank JB; Ohren JF; Gowan RC; Omer C; Camp HS; Esmaeil N; Moore K; Sebolt-Leopold JS; Pryzbranowski S; Merriman RL; Ortwine DF; Warmus JS; Flamme CM; Pavlovsky AG; Tecle H
J Med Chem; 2007 Oct; 50(21):5090-102. PubMed ID: 17880056
[TBL] [Abstract][Full Text] [Related]
4. Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors.
D'Angelo ND; Kim TS; Andrews K; Booker SK; Caenepeel S; Chen K; D'Amico D; Freeman D; Jiang J; Liu L; McCarter JD; San Miguel T; Mullady EL; Schrag M; Subramanian R; Tang J; Wahl RC; Wang L; Whittington DA; Wu T; Xi N; Xu Y; Yakowec P; Yang K; Zalameda LP; Zhang N; Hughes P; Norman MH
J Med Chem; 2011 Mar; 54(6):1789-811. PubMed ID: 21332118
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17.
Kiga M; Tanzawa F; Iwasaki S; Inaba F; Fujiwara K; Iwadare H; Echigo T; Nakamura Y; Shibata T; Suzuki K; Yasumatsu I; Nakayama A; Sasazawa Y; Tashiro E; Imoto M; Kurakata S
Anticancer Drugs; 2012 Jan; 23(1):119-30. PubMed ID: 22008853
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors.
Medina JR; Becker CJ; Blackledge CW; Duquenne C; Feng Y; Grant SW; Heerding D; Li WH; Miller WH; Romeril SP; Scherzer D; Shu A; Bobko MA; Chadderton AR; Dumble M; Gardiner CM; Gilbert S; Liu Q; Rabindran SK; Sudakin V; Xiang H; Brady PG; Campobasso N; Ward P; Axten JM
J Med Chem; 2011 Mar; 54(6):1871-95. PubMed ID: 21341675
[TBL] [Abstract][Full Text] [Related]
7. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.
Iverson C; Larson G; Lai C; Yeh LT; Dadson C; Weingarten P; Appleby T; Vo T; Maderna A; Vernier JM; Hamatake R; Miner JN; Quart B
Cancer Res; 2009 Sep; 69(17):6839-47. PubMed ID: 19706763
[TBL] [Abstract][Full Text] [Related]
8. The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents.
Laufer R; Forrest B; Li SW; Liu Y; Sampson P; Edwards L; Lang Y; Awrey DE; Mao G; Plotnikova O; Leung G; Hodgson R; Beletskaya I; Mason JM; Luo X; Wei X; Yao Y; Feher M; Ban F; Kiarash R; Green E; Mak TW; Pan G; Pauls HW
J Med Chem; 2013 Aug; 56(15):6069-87. PubMed ID: 23829549
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of Polo-like kinase 1 (MLN0905).
Duffey MO; Vos TJ; Adams R; Alley J; Anthony J; Barrett C; Bharathan I; Bowman D; Bump NJ; Chau R; Cullis C; Driscoll DL; Elder A; Forsyth N; Frazer J; Guo J; Guo L; Hyer ML; Janowick D; Kulkarni B; Lai SJ; Lasky K; Li G; Li J; Liao D; Little J; Peng B; Qian MG; Reynolds DJ; Rezaei M; Scott MP; Sells TB; Shinde V; Shi QJ; Sintchak MD; Soucy F; Sprott KT; Stroud SG; Nestor M; Visiers I; Weatherhead G; Ye Y; D'Amore N
J Med Chem; 2012 Jan; 55(1):197-208. PubMed ID: 22070629
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and evaluation of novel benzimidazoles, benzothiazoles and benzofurans incorporating pyrazole moiety as antiangiogenic agents.
Rida SM; Youssef AM; Badr MH; Malki A; Sherif ZA; Sultan AS
Arzneimittelforschung; 2012 Feb; 62(2):63-74. PubMed ID: 22344550
[TBL] [Abstract][Full Text] [Related]
11. Rational evolution of a novel type of potent and selective proviral integration site in Moloney murine leukemia virus kinase 1 (PIM1) inhibitor from a screening-hit compound.
Nakano H; Saito N; Parker L; Tada Y; Abe M; Tsuganezawa K; Yokoyama S; Tanaka A; Kojima H; Okabe T; Nagano T
J Med Chem; 2012 Jun; 55(11):5151-64. PubMed ID: 22540945
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, anticancer activity and docking of some substituted benzothiazoles as tyrosine kinase inhibitors.
Bhuva HA; Kini SG
J Mol Graph Model; 2010 Aug; 29(1):32-7. PubMed ID: 20493747
[TBL] [Abstract][Full Text] [Related]
13. Discovery of highly potent and selective pan-Aurora kinase inhibitors with enhanced in vivo antitumor therapeutic index.
Liu G; Abraham S; Tran L; Vickers TD; Xu S; Hadd MJ; Quiambao S; Holladay MW; Hua H; Ford Pulido JM; Gunawardane RN; Davis MI; Eichelberger SR; Apuy JL; Gitnick D; Gardner MF; James J; Breider MA; Belli B; Armstrong RC; Treiber DK
J Med Chem; 2012 Apr; 55(7):3250-60. PubMed ID: 22380736
[TBL] [Abstract][Full Text] [Related]
14. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
Hoeflich KP; O'Brien C; Boyd Z; Cavet G; Guerrero S; Jung K; Januario T; Savage H; Punnoose E; Truong T; Zhou W; Berry L; Murray L; Amler L; Belvin M; Friedman LS; Lackner MR
Clin Cancer Res; 2009 Jul; 15(14):4649-64. PubMed ID: 19567590
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy.
Wong H; Belvin M; Herter S; Hoeflich KP; Murray LJ; Wong L; Choo EF
J Pharmacol Exp Ther; 2009 Apr; 329(1):360-7. PubMed ID: 19147858
[TBL] [Abstract][Full Text] [Related]
16. Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor.
Brasca MG; Amboldi N; Ballinari D; Cameron A; Casale E; Cervi G; Colombo M; Colotta F; Croci V; D'Alessio R; Fiorentini F; Isacchi A; Mercurio C; Moretti W; Panzeri A; Pastori W; Pevarello P; Quartieri F; Roletto F; Traquandi G; Vianello P; Vulpetti A; Ciomei M
J Med Chem; 2009 Aug; 52(16):5152-63. PubMed ID: 19603809
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and SAR of inhibitors of protein kinase CK2: novel tricyclic quinoline analogs.
Haddach M; Pierre F; Regan CF; Borsan C; Michaux J; Stefan E; Kerdoncuff P; Schwaebe MK; Chua PC; Siddiqui-Jain A; Macalino D; Drygin D; O'Brien SE; Rice WG; Ryckman DM
Bioorg Med Chem Lett; 2012 Jan; 22(1):45-8. PubMed ID: 22169261
[TBL] [Abstract][Full Text] [Related]
18. Potent, selective, and orally bioavailable inhibitors of mammalian target of rapamycin (mTOR) kinase based on a quaternary substituted dihydrofuropyrimidine.
Cohen F; Bergeron P; Blackwood E; Bowman KK; Chen H; Dipasquale AG; Epler JA; Koehler MF; Lau K; Lewis C; Liu L; Ly CQ; Malek S; Nonomiya J; Ortwine DF; Pei Z; Robarge KD; Sideris S; Trinh L; Truong T; Wu J; Zhao X; Lyssikatos JP
J Med Chem; 2011 May; 54(9):3426-35. PubMed ID: 21495671
[TBL] [Abstract][Full Text] [Related]
19. Acylpyrogallols as inhibitors of antiapoptotic Bcl-2 proteins.
Tang G; Nikolovska-Coleska Z; Qiu S; Yang CY; Guo J; Wang S
J Med Chem; 2008 Feb; 51(4):717-20. PubMed ID: 18237106
[TBL] [Abstract][Full Text] [Related]
20. Identification of isothiazole-4-carboxamidines derivatives as a novel class of allosteric MEK1 inhibitors.
El Abdellaoui H; Varaprasad CV; Barawkar D; Chakravarty S; Maderna A; Tam R; Chen H; Allan M; Wu JZ; Appleby T; Yan S; Zhang W; Lang S; Yao N; Hamatake R; Hong Z
Bioorg Med Chem Lett; 2006 Nov; 16(21):5561-6. PubMed ID: 16934458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
